BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 37668041)

  • 1. Nanodelivery systems: An efficient and target-specific approach for drug-resistant cancers.
    Ashique S; Garg A; Hussain A; Farid A; Kumar P; Taghizadeh-Hesary F
    Cancer Med; 2023 Sep; 12(18):18797-18825. PubMed ID: 37668041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.
    Yadav P; Ambudkar SV; Rajendra Prasad N
    J Nanobiotechnology; 2022 Sep; 20(1):423. PubMed ID: 36153528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanodelivery Systems as a Novel Strategy to Overcome Treatment Failure of Cancer.
    He S; Gou X; Zhang S; Zhang X; Huang H; Wang W; Yi L; Zhang R; Duan Z; Zhou P; Qian Z; Gao X
    Small Methods; 2024 Jan; 8(1):e2301127. PubMed ID: 37849248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel nanomedicines to overcome cancer multidrug resistance.
    Su Z; Dong S; Zhao SC; Liu K; Tan Y; Jiang X; Assaraf YG; Qin B; Chen ZS; Zou C
    Drug Resist Updat; 2021 Sep; 58():100777. PubMed ID: 34481195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance.
    Tekchandani P; Kurmi BD; Paliwal SR
    Mini Rev Med Chem; 2017; 17(18):1793-1810. PubMed ID: 26891930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models.
    Petrikaite V; D'Avanzo N; Celia C; Fresta M
    Drug Resist Updat; 2023 May; 68():100956. PubMed ID: 36958083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies to overcome taxane resistance in cancer.
    Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
    Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amalgamation of Nanotechnology for Delivery of Bioactive Constituents in Solid Tumors.
    Parveen R; Mohapatra S; Ahmad S; Husain SA
    Curr Drug Deliv; 2023; 20(5):457-482. PubMed ID: 35469568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system.
    Sun X; Zhao P; Lin J; Chen K; Shen J
    Cancer Drug Resist; 2023; 6(2):390-415. PubMed ID: 37457134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-drug codelivery nanosystems: An emerging approach for overcoming cancer multidrug resistance.
    Gong J; Shi T; Liu J; Pei Z; Liu J; Ren X; Li F; Qiu F
    Biomed Pharmacother; 2023 May; 161():114505. PubMed ID: 36921532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The reversal of chemotherapy-induced multidrug resistance by nanomedicine for cancer therapy.
    Liu S; Khan AR; Yang X; Dong B; Ji J; Zhai G
    J Control Release; 2021 Jul; 335():1-20. PubMed ID: 33991600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics of Nanomedicine in Tumor Spheroid as an
    Roy SM; Garg V; Barman S; Ghosh C; Maity AR; Ghosh SK
    Front Bioeng Biotechnol; 2021; 9():785937. PubMed ID: 34926430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovative nanochemotherapy for overcoming cancer multidrug resistance.
    Tan H; Zhang M; Wang Y; Timashev P; Zhang Y; Zhang S; Liang XJ; Li F
    Nanotechnology; 2021 Nov; 33(5):. PubMed ID: 34700307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology.
    Xue X; Liang XJ
    Chin J Cancer; 2012 Feb; 31(2):100-9. PubMed ID: 22237039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer.
    Lee WH; Loo CY; Leong CR; Young PM; Traini D; Rohanizadeh R
    Expert Opin Drug Deliv; 2017 Aug; 14(8):937-957. PubMed ID: 27759437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.
    Milane L; Ganesh S; Shah S; Duan ZF; Amiji M
    J Control Release; 2011 Oct; 155(2):237-47. PubMed ID: 21497176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicines for combating multidrug resistance of cancer.
    Zhu YX; Jia HR; Duan QY; Wu FG
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1715. PubMed ID: 33860622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.